Cisplatin-based combination therapy for cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cisplatin (cis-diamminedichloroplatinum) is a widely used chemotherapy agent for various solid tumors.
• Its anticancer activity stems from DNA binding and adduct formation, inducing apoptosis.
• However, cisplatin use is limited by significant toxicities and acquired drug resistance.

Purpose of the Study:

• To review the molecular mechanisms underlying cisplatin's action.
• To explore combination drug therapies aimed at overcoming cisplatin resistance.
• To discuss strategies for mitigating cisplatin's adverse toxicological effects.

Main Methods:

• Literature review of cisplatin's molecular mechanisms.
• Analysis of signaling pathways involved in cisplatin-induced apoptosis (e.g., p53, MAPK, Akt).
• Examination of studies on combination therapies and their impact on efficacy and toxicity.

Main Results:

• Cisplatin induces apoptosis via DNA damage and activation of stress-response pathways.
• Drug resistance mechanisms and toxicities (hepatotoxicity, cardiotoxicity, neurotoxicity) are significant challenges.
• Combination therapies show promise in enhancing efficacy and reducing side effects.

Conclusions:

• Understanding cisplatin's molecular action is crucial for optimizing cancer treatment.
• Combination strategies are essential for overcoming resistance and managing toxicity.
• Further research into novel therapeutic combinations can improve patient outcomes in cisplatin-based chemotherapy.